Pulmatrix, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 945 CONCORD STREET, FRAMINGHAM, MA, 01701
Mailing Address 945 CONCORD STREET, FRAMINGHAM, MA, 01701
Phone (888) 355-4440
Fiscal Year End 1231
EIN 461821392
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| 8-K Current report of material events | October 16, 2025 | View on SEC |
| 10-Q Quarterly financial report | October 16, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 6, 2025 | View on SEC |
| 8-K Current report of material events | August 6, 2025 | View on SEC |
| 8-K Current report of material events | June 16, 2025 | View on SEC |
Annual Reports
10-K February 26, 2026
- Pulmatrix utilizes its proprietary iSPERSE™ technology to develop innovative inhaled medicines for conditions like migraines, COPD, and ABPA.
- The company is undergoing a pivotal strategic shift with a proposed merger with Cullgen Inc., which has received shareholder approval.
Material Events
8-K Acquisition March 27, 2026
High Impact
- Strategic pivot to high-growth senolytic longevity therapies
- Reverse takeover by Eos SENOLYTIX to access public markets
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.